AU2002226086C1 - Silensed anti-CD28 antibodies and use thereof - Google Patents

Silensed anti-CD28 antibodies and use thereof Download PDF

Info

Publication number
AU2002226086C1
AU2002226086C1 AU2002226086A AU2002226086A AU2002226086C1 AU 2002226086 C1 AU2002226086 C1 AU 2002226086C1 AU 2002226086 A AU2002226086 A AU 2002226086A AU 2002226086 A AU2002226086 A AU 2002226086A AU 2002226086 C1 AU2002226086 C1 AU 2002226086C1
Authority
AU
Australia
Prior art keywords
antibody
seq
cells
expression
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2002226086A
Other languages
English (en)
Other versions
AU2002226086A1 (en
AU2002226086B2 (en
Inventor
Yasuyuki Higashi
Paul Hinton
Nobuo Seki
Kouichi Tamura
J. Yun Tso
Hirotsugu Ueda
Maximiliano Vasquez
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Astellas Pharma Inc
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Publication of AU2002226086A1 publication Critical patent/AU2002226086A1/en
Application granted granted Critical
Publication of AU2002226086B2 publication Critical patent/AU2002226086B2/en
Assigned to ASTELLAS PHARMA, INC. reassignment ASTELLAS PHARMA, INC. Request for Assignment Assignors: FUJISAWA PHARMACEUTICAL CO., LTD.
Publication of AU2002226086C1 publication Critical patent/AU2002226086C1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Surgery (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2002226086A 2000-12-14 2001-12-14 Silensed anti-CD28 antibodies and use thereof Ceased AU2002226086C1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25515500P 2000-12-14 2000-12-14
US60/255,155 2000-12-14
PCT/US2001/047955 WO2002047721A1 (en) 2000-12-14 2001-12-14 Silensed anti-cd28 antibodies and use thereof

Publications (3)

Publication Number Publication Date
AU2002226086A1 AU2002226086A1 (en) 2002-08-29
AU2002226086B2 AU2002226086B2 (en) 2005-08-25
AU2002226086C1 true AU2002226086C1 (en) 2006-03-09

Family

ID=22967074

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2002226086A Ceased AU2002226086C1 (en) 2000-12-14 2001-12-14 Silensed anti-CD28 antibodies and use thereof
AU2608602A Pending AU2608602A (en) 2000-12-14 2001-12-14 Silensed anti-cd28 antibodies and use thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2608602A Pending AU2608602A (en) 2000-12-14 2001-12-14 Silensed anti-cd28 antibodies and use thereof

Country Status (18)

Country Link
EP (1) EP1341553A4 (es)
JP (1) JP2004515243A (es)
KR (1) KR20040020866A (es)
CN (1) CN1272345C (es)
AR (1) AR031924A1 (es)
AU (2) AU2002226086C1 (es)
BR (1) BR0116686A (es)
CA (1) CA2432736A1 (es)
CZ (1) CZ20031909A3 (es)
HU (1) HUP0400697A3 (es)
IL (1) IL156262A0 (es)
MX (1) MXPA03005327A (es)
NO (1) NO20032542L (es)
NZ (1) NZ526569A (es)
PL (1) PL363239A1 (es)
RU (1) RU2261723C2 (es)
WO (1) WO2002047721A1 (es)
ZA (1) ZA200305384B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080095774A1 (en) * 2001-02-16 2008-04-24 Wyeth Agents and Methods for Specifically Blocking CD28-Mediated Signaling
US7531168B2 (en) 2001-02-16 2009-05-12 Genetics Institute Llc Method for downmodulating immune response in type I diabetes
BRPI0611901A2 (pt) 2005-06-14 2012-08-28 Amgen, Inc composição, liofilizado, kit, e, processo para preparar uma composição
FR2951176A1 (fr) 2009-10-09 2011-04-15 Tcl Pharma Ligands monovalents du recepteur cd28 humain
WO2011101791A1 (en) * 2010-02-18 2011-08-25 Tcl Pharma Anti-cd28 humanized antibodies
AU2017345490B2 (en) 2016-10-21 2022-07-07 Amgen Inc. Pharmaceutical formulations and methods of making the same
KR20210035805A (ko) 2018-06-15 2021-04-01 플래그쉽 파이어니어링 이노베이션스 브이, 인크. 세포후 신호전달 인자의 조절을 통한 면역 활성의 증가
WO2020183471A1 (en) * 2019-03-14 2020-09-17 Biond Biologics Ltd. A method for immunosuppression
MA55805A (fr) 2019-05-03 2022-03-09 Flagship Pioneering Innovations V Inc Métodes de modulation de l'activité immunitaire
JP2023509359A (ja) 2019-12-17 2023-03-08 フラグシップ パイオニアリング イノベーションズ ブイ，インコーポレーテッド 鉄依存性細胞分解の誘導物質との併用抗癌療法
CN116096906A (zh) 2020-06-29 2023-05-09 旗舰创业创新五公司 工程化以促进萨诺传递的病毒及其在治疗癌症中的用途
IL300666A (en) 2020-08-19 2023-04-01 Xencor Inc ANTI–CD28 COMPOSITIONS
KR20230165276A (ko) 2021-03-31 2023-12-05 플래그쉽 파이어니어링 이노베이션스 브이, 인크. 타노트랜스미션 폴리펩티드 및 암의 치료에서의 이의 용도
EP4363059A1 (en) 2021-06-29 2024-05-08 Flagship Pioneering Innovations V, Inc. Immune cells engineered to promote thanotransmission and uses thereof
WO2024040195A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
WO2024077191A1 (en) 2022-10-05 2024-04-11 Flagship Pioneering Innovations V, Inc. Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6641809B1 (en) * 1990-03-26 2003-11-04 Bristol-Myers Squibb Company Method of regulating cellular processes mediated by B7 and CD28

Also Published As

Publication number Publication date
NO20032542D0 (no) 2003-06-05
JP2004515243A (ja) 2004-05-27
CZ20031909A3 (cs) 2003-11-12
HUP0400697A2 (hu) 2004-06-28
HUP0400697A3 (en) 2007-05-02
CN1489473A (zh) 2004-04-14
IL156262A0 (en) 2004-01-04
RU2003121231A (ru) 2005-02-10
EP1341553A1 (en) 2003-09-10
MXPA03005327A (es) 2004-12-03
EP1341553A4 (en) 2004-07-28
NO20032542L (no) 2003-08-07
RU2261723C2 (ru) 2005-10-10
KR20040020866A (ko) 2004-03-09
CA2432736A1 (en) 2002-06-20
ZA200305384B (en) 2004-10-11
CN1272345C (zh) 2006-08-30
PL363239A1 (en) 2004-11-15
NZ526569A (en) 2005-07-29
AU2002226086B2 (en) 2005-08-25
WO2002047721A1 (en) 2002-06-20
AR031924A1 (es) 2003-10-08
BR0116686A (pt) 2003-12-30
AU2608602A (en) 2002-06-24

Similar Documents

Publication Publication Date Title
RU2244720C2 (ru) Антитело igg с аффинностью связывания в отношении антигенного комплекса cd3, рекомбинантные нуклеиновые кислоты, кодирующие легкую и тяжелую цепи антитела, способ получения системы, способ получения антитела, способ лечения пациента
EP0966485B1 (en) MUTATED NONACTIVATING IgG2 DOMAINS AND ANTI-CD3 ANTIBODIES INCORPORATING THE SAME
CA2212750C (en) Humanized antibodies against cd3
AU751064B2 (en) Antibodies against human CD40
KR100191152B1 (ko) Cd4 특이적 재조합 항체
AU2002226086C1 (en) Silensed anti-CD28 antibodies and use thereof
US20040052783A1 (en) Humanized antibodies against CD3
US5951983A (en) Methods of inhibiting T cell mediated immune responses with humanized LO-CD2A-specific antibodies
AU754185B2 (en) LO-CD2a antibody and uses thereof for inhibiting T cell activation and proliferation
CA2544365A1 (en) Modified anti-cd52 antibody
AU2002226086A1 (en) Silensed anti-CD28 antibodies and use thereof
US20040116675A1 (en) Silenced anti-cd28 antibodies and use thereof

Legal Events

Date Code Title Description
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 04 OCT 2005.

FGA Letters patent sealed or granted (standard patent)
TC Change of applicant's name (sec. 104)

Owner name: ASTELLAS PHARMA, INC.

Free format text: FORMER NAME: FUJISAWA PHARMACEUTICAL CO., LTD.

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 04 OCT 2005

MK14 Patent ceased section 143(a) (annual fees not paid) or expired